SARS-CoV-2 infection in patients with primary central nervous system lymphoma

ConclusionThis preliminary analysis suggests that, while being at higher risk be for severe illness, PCNSL patients with COVID-19 might be treated maximally especially if they achieved oncological response at the time of SARS-CoV-2 infection. Chemotherapy might be resumed without prolonged delay in PCNSL patients with COVID-19.

Source: Journal of Neurology - January 2, 2021 Category: Neurology Source Type: research